Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10086142 | 0.86 | ALDH1A1 (0.58) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL18548898 | 0.86 | MAPT (0.46) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL18548810 | 0.84 | SMN1; SMN2 (0.47) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL10086141 | 0.84 | KDM4E (0.48) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL10085037 | 0.83 | EGFR (0.43) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL18548808 | 0.83 | AXL (0.43) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL18548857 | 0.83 | MAPT (0.67) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL10085033 | 0.82 | MAPT (0.47) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL10084705 | 0.81 | GFER (0.45) | KDM4EMAPTGAAHSD17B10ALDH1A1 | |
| SCHEMBL10084680 | 0.76 | KDM4E (0.38) | KDM4EMAPTGAAHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339294-B1 | QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | JINAN UNIVERSITY (CN) | 2018-09-20 | — | — | US | disclosed |
| EP-3339294-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER | Jinan University (CN) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017028797-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER | 暨南大学 | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NRAS, AXL, ABL1 | KDM4E 1861/4885MAPT 4122/4885GAA 1090/4885 |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | NRAS, AXL, ABL1 | KDM4E 1861/4885MAPT 4122/4885GAA 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.